Coupa Software (COUP) earnings and revenue topped first-quarter analyst estimates while revenue guidance edged by Wall Street targets. The Coupa earnings news sent the software maker’s stock down in extended trading Monday.
X
Coupa earnings soared 566% to 20 cents per adjusted share for the quarter ending April 30.
Revenue rose 47% to $119.2 million, the company said. Subscription revenue rose 45% to $105.7 million. Analysts expected Coupa earnings of 7 cents a share on revenue of $111.5 million.
A year earlier, Coupa earned 3 cents a share on sales of $81.3 million. The Coupa earnings report included the recent acquisitions of Hipperos and Exari.
Coupa stock fell 4% to near 212 in extended trading on the stock market today.
Coupa Earnings Guidance Edges By Estimates
In Monday’s regular session, Coupa stock rose 1.8%. Heading into the Coupa earnings report, the company’s stock owned a Relative Strength Rating of 95 out of a possible 99.
For the current quarter ending in July, Coupa forecast revenue of $118.5 million at the midpoint of its guidance vs. estimates of $117 million.
For the full-year, Coupa said it expects revenue of $490 million vs. estimates of $488 million.
In addition, Coupa’s core market is selling business spending management software. Further, Coupa’s software products cover employee travel and expense management, procurement and invoicing.
The company in November 2018 rolled out Coupa Pay, a business-to-business payment and financing product.
San Mateo, Calif.-based Coupa competes against SAP‘s (SAP) Ariba unit, Fleetcor‘s (FLT) Nvoicepay, Basware, Jaggaer, Zycus, Ivalua, and AvidXchange. A new rival is Workday (WDAY), which acquired Scout RFP for $540 million last year.
Follow Reinhardt Krause on Twitter @reinhardtk_tech for updates on 5G wireless, artificial intelligence, cybersecurity and cloud computing.
YOU MAY ALSO LIKE
IBD Live: A New Tool For Daily Stock Market Analysis
Find Compelling Growth Stocks With IBD’s Stock Of The Day
View Breakout Stocks & Technical Analysis
Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists
Get A Free Trial Of IBD Leaderboard
